Pharmaceutical giant Bristol-Myers Squibb (BMY) saw its stock plummet 5.38% in pre-market trading on Thursday, following its mixed fourth-quarter results and below-par guidance for 2025.
For Q4, BMY posted earnings of $1.67 per share, surpassing analyst estimates of $1.46. However, revenue of $12.34 billion, though higher than expected, grew only 8% year-over-year. Flagship products like cancer drug Opdivo saw modest 4% sales growth.
The main cause for concern was BMY's guidance for 2025. The company expects revenue of around $45.5 billion for the year, well short of the $47.4 billion analysts had projected. This lower top-line outlook stems from intensifying generic competition impacting sales of older drugs like Revlimid, Pomalyst, Sprycel, and Abraxane.
BMY's earnings guidance of $6.55 to $6.85 per share for 2025 also fell short of the $6.92 consensus estimate. In response, the company revealed plans to expand its cost-cutting program by an additional $2 billion through 2027, bringing total targeted savings to $3.5 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.